Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Scientific Reports
|
June 30, 2021
The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population
Sarah E Pape, Tamara Al Janabi, Nicholas J Ashton, et al.
Archives of Biochemistry and Biophysics
|
August 9, 2005
Role of the snake venom toxin jararhagin in proinflammatory pathogenesis: in vitro and in vivo gene expression analysis of the effects of the toxin
Paul Gallagher, Yongde Bao, Solange M T Serrano, et al.
Journal for Immunotherapy of Cancer
|
January 18, 2019
Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence
Katey S S Enfield, Spencer D Martin, Erin A Marshall, et al.
Multiple Sclerosis and Related Disorders
|
June 3, 2025
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement
Ruth Dobson, Tarunya Arun, James Varley, et al.
Therapeutic Advances in Drug Safety
|
January 11, 2018
Incident adverse drug reactions in geriatric inpatients: a multicentred observational study
Amanda Lavan, Joseph Eustace, Darren Dahly, et al.
Social Science & Medicine (1982)
|
December 23, 2023
'Ageing well': Discursive constructions of ageing and health in the public reach of a national longitudinal study on ageing
Gerard Fealy, Matteo Di Placido, Deirdre O'Donnell, et al.
Psychology, Health & Medicine
|
September 23, 2024
From the ground up: stakeholders' representations of the Irish longitudinal study on ageing (TILDA)
Yeter Sinem Üzar-Özçetin, Michael Connolly, Timmy Frawley, et al.
Multiple Sclerosis and Related Disorders
|
May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
Age and Ageing
|
June 24, 2021
Corrigendum to: Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial
Denis O'Mahony, Adalsteinn Gudmundsson, Roy L Soiza, et al.
Age and Ageing
|
June 3, 2020
Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial
Denis O'Mahony, Adalsteinn Gudmundsson, Roy L Soiza, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Scientific Reports
|
June 30, 2021
The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population
Sarah E Pape, Tamara Al Janabi, Nicholas J Ashton, et al.
Archives of Biochemistry and Biophysics
|
August 9, 2005
Role of the snake venom toxin jararhagin in proinflammatory pathogenesis: in vitro and in vivo gene expression analysis of the effects of the toxin
Paul Gallagher, Yongde Bao, Solange M T Serrano, et al.
Journal for Immunotherapy of Cancer
|
January 18, 2019
Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence
Katey S S Enfield, Spencer D Martin, Erin A Marshall, et al.
Multiple Sclerosis and Related Disorders
|
June 3, 2025
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement
Ruth Dobson, Tarunya Arun, James Varley, et al.
Therapeutic Advances in Drug Safety
|
January 11, 2018
Incident adverse drug reactions in geriatric inpatients: a multicentred observational study
Amanda Lavan, Joseph Eustace, Darren Dahly, et al.
Social Science & Medicine (1982)
|
December 23, 2023
'Ageing well': Discursive constructions of ageing and health in the public reach of a national longitudinal study on ageing
Gerard Fealy, Matteo Di Placido, Deirdre O'Donnell, et al.
Psychology, Health & Medicine
|
September 23, 2024
From the ground up: stakeholders' representations of the Irish longitudinal study on ageing (TILDA)
Yeter Sinem Üzar-Özçetin, Michael Connolly, Timmy Frawley, et al.
Multiple Sclerosis and Related Disorders
|
May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
Age and Ageing
|
June 24, 2021
Corrigendum to: Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial
Denis O'Mahony, Adalsteinn Gudmundsson, Roy L Soiza, et al.
Age and Ageing
|
June 3, 2020
Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial
Denis O'Mahony, Adalsteinn Gudmundsson, Roy L Soiza, et al.
Page
of 10